PT1642576E - Utilização de derivados de pirrole para combate da ansiedade - Google Patents

Utilização de derivados de pirrole para combate da ansiedade Download PDF

Info

Publication number
PT1642576E
PT1642576E PT05028364T PT05028364T PT1642576E PT 1642576 E PT1642576 E PT 1642576E PT 05028364 T PT05028364 T PT 05028364T PT 05028364 T PT05028364 T PT 05028364T PT 1642576 E PT1642576 E PT 1642576E
Authority
PT
Portugal
Prior art keywords
compound
pyrrole derivatives
isoindolinone
prodrug
chloro
Prior art date
Application number
PT05028364T
Other languages
English (en)
Portuguese (pt)
Inventor
Cathyrn Montgomery Clary
Sean David Donevan
Perry Steven Eisman
Richard J Kavoussi
Lyou-Fu Ma
Jeroen Bernard Van Beek
Atul Chandra Pande
Original Assignee
Indevus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indevus Pharmaceuticals Inc filed Critical Indevus Pharmaceuticals Inc
Publication of PT1642576E publication Critical patent/PT1642576E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT05028364T 2001-04-30 2002-04-16 Utilização de derivados de pirrole para combate da ansiedade PT1642576E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28754501P 2001-04-30 2001-04-30

Publications (1)

Publication Number Publication Date
PT1642576E true PT1642576E (pt) 2009-05-21

Family

ID=23103396

Family Applications (1)

Application Number Title Priority Date Filing Date
PT05028364T PT1642576E (pt) 2001-04-30 2002-04-16 Utilização de derivados de pirrole para combate da ansiedade

Country Status (20)

Country Link
US (2) US7026332B2 (enExample)
EP (2) EP1642576B1 (enExample)
JP (1) JP2002326934A (enExample)
KR (1) KR20020084413A (enExample)
CN (1) CN1384104A (enExample)
AT (2) ATE331513T1 (enExample)
AU (1) AU783516B2 (enExample)
CA (1) CA2383599C (enExample)
CY (1) CY1109129T1 (enExample)
DE (2) DE60231568D1 (enExample)
DK (1) DK1642576T3 (enExample)
ES (2) ES2323646T3 (enExample)
HU (1) HU228826B1 (enExample)
IL (2) IL149280A0 (enExample)
MY (1) MY129575A (enExample)
NZ (1) NZ518615A (enExample)
PL (2) PL207725B1 (enExample)
PT (1) PT1642576E (enExample)
TW (1) TWI302455B (enExample)
ZA (1) ZA200203347B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0410419A (pt) * 2003-05-16 2006-05-30 Pfizer Prod Inc tratamento para a ansiedade com ziprasidona
JP2007502856A (ja) * 2003-05-16 2007-02-15 ファイザー・プロダクツ・インク 精神病性障害および抑うつ性障害の治療
ATE449633T1 (de) * 2003-09-12 2009-12-15 Pfizer Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
WO2005025563A1 (en) * 2003-09-12 2005-03-24 Warner-Lambert Company Llc Combination comprising an alpha-2-delta ligand and an ssri and/or snri for treatment of depression and anxiety disorders
WO2005105061A2 (en) * 2004-04-14 2005-11-10 Indevus Pharmaceuticals, Inc. Transdermal patch
EP1744750A2 (en) * 2004-05-06 2007-01-24 Sandoz AG Pharmaceutical composition comprising hydrophobic drug having improved solubility
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
EP2678337A1 (en) * 2011-02-25 2014-01-01 Concert Pharmaceuticals Inc. 2-amino-naphthyridine derivatives
WO2020191047A1 (en) * 2019-03-18 2020-09-24 Neurocycle Therapeutics, Inc. Use of gabaa receptor modulators for treatment of pain

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2607503B1 (fr) 1986-12-02 1989-02-24 Rhone Poulenc Sante Nouveaux derives de l'isoindolinone, leur preparation et les compositions pharmaceutiques qui les contiennent
DE3814022A1 (de) * 1988-04-26 1989-11-09 Davy Mckee Ag Verfahren zur herstellung linearer polyester, insbesondere fuer filme und folien
EP0521622B1 (en) 1991-07-03 1997-08-13 PHARMACIA & UPJOHN COMPANY Pyrazolopyrimidine and pyrimidinyl bisphosphonic esters as anti-inflammatories
FR2678932B1 (fr) 1991-07-12 1993-09-24 Rhone Poulenc Rorer Sa Procede de preparation des isomeres optiques d'un derive de l'amino-2 naphtyridine.
FR2678934B1 (fr) 1991-07-12 1995-01-13 Rhone Poulenc Rorer Sa Procede de preparation de l'isomere dextrogyre d'un derive de l'isoindolinone.
FR2681068B1 (fr) 1991-09-09 1993-11-19 Rhone Poulenc Rorer Sa Procede de preparation de l'isomere dextrogyre d'un derive de l'isoindolinone.
FR2684673B1 (fr) 1991-12-04 1994-01-21 Rhone Poulenc Rorer Sa Procede de preparation d'un derive de l'amino-2 naphtyridine racemique.
FR2687154B1 (fr) * 1992-02-07 1995-05-12 Rhone Poulenc Rorer Sa Nouveau derive de l'isoindolinone, sa preparation et les compositions pharmaceutiques qui le contiennent.
FR2695389B1 (fr) 1992-09-08 1994-11-04 Rhone Poulenc Rorer Sa Nouveau dérivé de l'isoindolinone, sa préparation et les compositions pharmaceutiques qui le contiennent.
US5498716A (en) 1994-01-12 1996-03-12 Rhone-Poulenc Rorer S.A. 2-amino naphthyridine derivative, its preparation and its use
GB2305859A (en) * 1996-03-29 1997-04-23 Lilly Co Eli Treatment of obsessive-compulsive disorder
US6362371B1 (en) * 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
WO2001008670A2 (en) * 1999-07-29 2001-02-08 Interneuron Pharmaceuticals, Inc. Methods and compositions for alleviating stuttering
DE19939980A1 (de) 1999-08-24 2001-03-01 Merck Patent Gmbh Inhibitoren des Integrins alphavbeta¶3¶
AU2756602A (en) * 2001-04-25 2002-10-31 Pfizer Products Inc. Methods and kits for treating depression or preventing deterioration of cognitive function

Also Published As

Publication number Publication date
DE60212757T2 (de) 2007-06-28
HU228826B1 (en) 2013-05-28
US7553847B2 (en) 2009-06-30
NZ518615A (en) 2004-03-26
HU0201394D0 (enExample) 2002-06-29
MY129575A (en) 2007-04-30
DE60212757D1 (de) 2006-08-10
ES2267943T3 (es) 2007-03-16
AU2760902A (en) 2002-10-31
PL353681A1 (en) 2002-11-04
AU783516B2 (en) 2005-11-03
US20060128746A1 (en) 2006-06-15
ES2323646T3 (es) 2009-07-22
DE60231568D1 (de) 2009-04-23
EP1254660A2 (en) 2002-11-06
CY1109129T1 (el) 2014-07-02
EP1642576A3 (en) 2007-01-10
ATE424820T1 (de) 2009-03-15
IL204665A (en) 2011-05-31
EP1642576B1 (en) 2009-03-11
DK1642576T3 (da) 2009-04-14
EP1254660A3 (en) 2003-03-26
ZA200203347B (en) 2003-11-26
HUP0201394A3 (en) 2003-12-29
PL207725B1 (pl) 2011-01-31
EP1254660B1 (en) 2006-06-28
ATE331513T1 (de) 2006-07-15
EP1642576A2 (en) 2006-04-05
US20030022915A1 (en) 2003-01-30
JP2002326934A (ja) 2002-11-15
PL390683A1 (pl) 2010-05-24
TWI302455B (en) 2008-11-01
IL149280A0 (en) 2002-11-10
PL207738B1 (pl) 2011-01-31
CA2383599A1 (en) 2002-10-30
HUP0201394A2 (hu) 2002-12-28
CA2383599C (en) 2006-10-31
US7026332B2 (en) 2006-04-11
CN1384104A (zh) 2002-12-11
KR20020084413A (ko) 2002-11-07
HK1094307A1 (en) 2007-03-30

Similar Documents

Publication Publication Date Title
HUS2100028I1 (hu) ERBB I. típusú receptor tirozinkináz-gátló N4-fenil-kinazolin-4-amin származékok és rokon vegyületeik a hiperproliferatív betegségek kezelésére
ATE440603T1 (de) 8-hydroxychinolinderivate
IL171976A0 (en) Indazole, benzisoxazole, and banzisothiazole kinase inhibitors
EA200401160A1 (ru) Производные тиазола и оксазола, которые модулируют активность ppar
WO2001019829A3 (en) Pyrazolopyrimidines as therapeutic agents
DK1333833T3 (da) Ny trisubstitueret 8H-pyridol[2,3-d]pyrimidin-7-on-forbindelse til behandling af CSBP/RK/p38-kinnasemedierede sygdomme
CA2288705A1 (en) Use of quinazoline compounds for the treatment of polycystic kidney disease
YU84603A (sh) Novi inhibitori tirozin kinaze
PA8537501A1 (es) Naftostirilos
UA93351C2 (uk) Похідні фталазіну як інгібітори parp
ATE522509T1 (de) Pyrimidylcyclopentane als inhibitoren der akt- proteinkinase
DK1578740T3 (da) 1,2,4-triaminobenzenderivater, der er egnede til behandling af lidelser i centralnervesystemet
DK2054418T3 (da) Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer
EA200801308A1 (ru) Комбинации, включающие ингибитор cdk и антитело фактора роста, или антимитотик
MXPA04006184A (es) Compuestos derivados de 1h-pirazolilo, para el uso en enfermedades asociadas con el receptor 5-ht2c.
ATE277072T1 (de) Sapogenin derivate zur behandlung von kognitiven störungen
CY1109129T1 (el) Χρηση παραγωγων πυρρολιου για καταπολεμηση του αγχους
BRPI0407841A (pt) inibidores heterocìclicos de quinase
ATE407923T1 (de) Tyrosinderivate als phosphatase inhibitoren
DE60142304D1 (de) Substituierte heterocyclische verbindungen und deren verwendung zur behandlung multipler medikamentenresistenz
DK1558610T3 (da) Substituerede aminoquinuclidinforbindelser og deres anvendelse som delta-opioidreceptorligander
DK1553938T3 (da) Anvendelse af epothilonderivater til behandling af hyperparathyroidisme
FR2827172B1 (fr) Derives de pyridin-2-yl-methylamine pour le traitement de la dependance aux opioides